Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.

Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.

CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.

Cidara Therapeutics has been given a lifeline after Johnson & Johnson’s opt-in on its universal flu prevention treatment – though the big pharma is expected to pass it onto a third party.